Xenetic Biosciences (NASDAQ:XBIO) and XTL Biopharmaceuticals (NASDAQ:XTLB) Head to Head Survey

Xenetic Biosciences (NASDAQ:XBIO) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Valuation and Earnings

This table compares Xenetic Biosciences and XTL Biopharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$3.26 million	1.57	-$2.68 million	($1.16)	-1.93
XTL Biopharmaceuticals	$450,000.00	11.32	-$6.97 million	($0.64)	-3.36

Xenetic Biosciences has higher revenue and earnings than XTL Biopharmaceuticals. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Xenetic Biosciences, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Xenetic Biosciences has a beta of 2.2, suggesting that its share price is 120% more volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Xenetic Biosciences and XTL Biopharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1	0	0	0	1.00
XTL Biopharmaceuticals	1	0	0	0	1.00

Insider and Institutional Ownership

15.1% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are held by institutional investors. 7.6% of Xenetic Biosciences shares are held by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Xenetic Biosciences and XTL Biopharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-75.90%	-40.62%	-34.97%
XTL Biopharmaceuticals	N/A	N/A	N/A

Summary

XTL Biopharmaceuticals beats Xenetic Biosciences on 6 of the 11 factors compared between the two stocks.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.